Characterization of CYP3A isozymes involved in the metabolism of domperidone: Role of cytochrome b5 and inhibition by ketoconazole

Drug Metabolism Letters

Volumn 4, Issue 2, 2010, Pages 95-103

  Michaud, Véronique ^a   Simard, Chantale ^b   Turgeon, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

CYP3A4; CYP3A5; Cytochrome b5; Cytochromes P450; Domperidone; Drug metabolism; Midazolam

Indexed keywords

4 HYDROXYMIDAZOLAM; 5 HYDROXYDOMPERIDONE; CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOMPERIDONE; DRUG METABOLITE; KETOCONAZOLE; MIDAZOLAM; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CYTOCHROME P450; DOPAMINE RECEPTOR BLOCKING AGENT; ISOENZYME;

ARTICLE; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; METABOLISM;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DOMPERIDONE; DOPAMINE ANTAGONISTS; HUMANS; HYDROXYLATION; IN VITRO TECHNIQUES; ISOENZYMES; KETOCONAZOLE; MICROSOMES, LIVER;

EID: 77953796074     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231210791292735     Document Type: Article

References (41)

1. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34 (1-2), 83-448.
2. Guengerich, F. P.; Martin, M. V.; Beaune, P. H.; Kremers, P.; Wolff, T.; Waxman, D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 1986, 261 (11), 5051-60.
3. Gellner, K.; Eiselt, R.; Hustert, E.; Arnold, H.; Koch, I.; Haberl, M.; Deglmann, C. J.; Burk, O.; Buntefuss, D.; Escher, S.; Bishop, C.; Koebe, H. G.; Brinkmann, U.; Klenk, H. P.; Kleine, K.; Meyer, U. A.; Wojnowski, L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 2001, 11 (2), 111-21.
4. Komori, M.; Nishio, K.; Fujitani, T.; Ohi, H.; Kitada, M.; Mima, S.; Itahashi, K.; Kamataki, T. Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers. Arch. Biochem. Biophys., 1989, 272 (1), 219-25.
5. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270 (1), 414-23.
6. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 pie. Drug Metab. Dispos., 2006, 34 (5), 880-6.
7. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27 (4), 383-391.
8. Harlow, G. R.; Halpert, J. R. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a sitedirected mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. U S A., 1998, 95 (12), 6636-41.
9. Kenworthy, K. E.; Clarke, S. E.; Andrews, J.; Houston, J. B. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos., 2001, 29 (12), 1644-51.
10. Schrag, M. L.; Wienkers, L. C. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch. Biochem. Biophys., 2001, 391 (1), 49-55.
11. Domanski, T. L.; He, Y. A.; Khan, K. K.; Roussel, F.; Wang, Q.; Halpert, J. R. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry, 2001, 40 (34), 10150-60.
12. Emoto, C.; Iwasaki, K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica, 2006, 36 (2-3), 219-33.
13. Shou, M.; Lin, Y.; Lu, P.; Tang, C.; Mei, Q.; Cui, D.; Tang, W.; Ngui, J. S.; Lin, C. C.; Singh, R.; Wong, B. K.; Yergey, J. A.; Lin, J. H.; Pearson, P. G.; Baillie, T. A.; Rodrigues, A. D.; Rushmore, T. H. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab., 2001, 2 (1), 17-36.
14. Galetin, A.; Clarke, S. E.; Houston, J. B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos., 2003, 31 (9), 1108-16.
15. Shen, L.; Fitzloff, J. F.; Cook, C. S. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos., 2004, 32 (2), 186-96.
16. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 1994, 33 (21), 6450-5.
17. Schrag, M. L.; Wienkers, L. C. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Adv. Exp. Med. Biol., 2001, 500, 347-50.
18. Drolet, B.; Rousseau, G.; Daleau, P.; Cardinal, R.; Turgeon, J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation, 2000, 102 (16), 1883-5.
19. Drolet, B.; Khalifa, M.; Daleau, P.; Hamelin, B. A.; Turgeon, J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation, 1998, 97 (2), 204-10.
20. Rocha, C. M.; Barbosa, M. M. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr. Cardiol., 2005, 26 (5), 720-3.
21. Giaccone, G.; Bertetto, O.; Calciati, A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet, 1984, 2 (8415), 1336-7.
22. Simard, C.; Michaud, V.; Gibbs, B.; Masse, R.; Lessard, E.; Turgeon, J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica, 2004, 34 (11-12), 1013-23.
23. Ward, B. A.; Morocho, A.; Kandil, A.; Galinsky, R. E.; Flockhart, D. A.; Desta, Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br. J. Clin. Pharmacol., 2004, 58 (3), 277-287.
24. Medicines Control Council. Interaction between ketoconazole and domperidone and the risk of QT prolongation-important safety information. S. Afr. Med. J., 2006, 96 (7), 596.
25. V.; Simard, C.; Turgeon, J. An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2007, 852 (1-2), 611-6.
26. Perloff, M. D.; von Moltke, L. L.; Court, M. H.; Kotegawa, T.; Shader, R. I.; Greenblatt, D. J. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther., 2000, 292 (2), 618-28.
27. Houston, J. B.; Kenworthy, K. E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos., 2000, 28 (3), 246-54.
28. Kronbach, T.; Mathys, D.; Umeno, M.; Gonzalez, F. J.; Meyer, U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol., 1989, 36 (1), 89-96.
29. Ghosal, A.; Satoh, H.; Thomas, P. E.; Bush, E.; Moore, D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab. Dispos., 1996, 24 (9), 940-7.
30. Schenkman, J. B.; Jansson, I. The many roles of cytochrome b5. Pharmacol. Ther., 2003, 97 (2), 139-52.
31. Yamazaki, H.; Johnson, W. W.; Ueng, Y. F.; Shimada, T.; Guengerich, F. P. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apocytochrome b5. J. Biol. Chem., 1996, 271 (44), 27438-44.
32. Shet, M. S.; Faulkner, K. M.; Holmans, P. L.; Fisher, C. W.; Estabrook, R. W. The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. Arch. Biochem. Biophys., 1995, 318 (2), 314-21.
33. Yamaori, S.; Yamazaki, H.; Suzuki, A.; Yamada, A.; Tani, H.; Kamidate, T.; Fujita, K.; Kamataki, T. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem. Pharmacol., 2003, 66 (12), 2333-40.
34. Yamazaki, H.; Nakamura, M.; Komatsu, T.; Ohyama, K.; Hatanaka, N.; Asahi, S.; Shimada, N.; Guengerich, F. P.; Shimada, T.; Nakajima, M.; Yokoi, T. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif., 2002, 24 (3), 329-37.
35. Hirota, N.; Ito, K.; Iwatsubo, T.; Green, C. E.; Tyson, C. A.; Shimada, N.; Suzuki, H.; Sugiyama, Y. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm. Drug Dispos., 2001, 22 (2), 53-71.
36. Nakajima, M.; Tane, K.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. J. Pharm. Sci., 2002, 91 (4), 952-63.
37. Galetin, A.; Brown, C.; Hallifax, D.; Ito, K.; Houston, J. B. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos., 2004, 32 (12), 1411-20.
38. Patki, K. C.; Von Moltke, L. L.; Greenblatt, D. J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos., 2003, 31 (7), 938-44.
39. Allqvist, A.; Miura, J.; Bertilsson, L.; Mirghani, R. A. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol., 2007, 63 (2), 173-9.
40. Williams, J. A.; Ring, B. J.; Cantrell, V. E.; Jones, D. R.; Eckstein, J.; Ruterbories, K.; Hamman, M. A.; Hall, S. D.; Wrighton, S. A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos., 2002, 30 (8), 883-91.
41. Heizmann, P.; Ziegler, W. H. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung, 1981, 31 (12a), 2220-3.